Caring Brands, Inc. (CABR) is a small wellness consumer-products company based in Fort Pierce, Florida, that develops and markets over-the-counter and cosmetic dermatology products, including the Hair Enzyme Booster for hair loss, Photocil for psoriasis and vitiligo, CB-101 for eczema, and the NoStingz sunscreen line. It generates only minimal revenue and carries a market capitalization of roughly $7 million.
In Wednesday's session, the shares traded at about $0.70, up $0.03 or 4.48%, against a previous close of $0.67. The stock is higher, but on no verified news: no press release, filing, analyst rating change, or corporate announcement was published ahead of the move. The advance follows a steep two-week slide that took the shares from $1.23 on November 3 to $0.67, and the session's own trading range of roughly $0.61 to $0.73 illustrates how unstable the quote has become.
No verified news or fundamental catalyst found explains today's gain. A review of company disclosures, newswire coverage, and regulatory filings showed nothing dated November 18, and nothing published earlier that had not already been absorbed by the market during the prior week's decline.
The most plausible explanation is technical, and it is an assessment rather than a confirmed fact. The stock lost about 45% in ten sessions through Tuesday, closing below every recent support level and pressing toward its 52-week low of $0.60. In names this small — the float is roughly 2.3 million shares — an exhausted seller base and a thin order book are often enough to produce a sharp bounce, and that pattern is consistent with today's action: a dip to $0.61 in the mid-morning, followed by a push to $0.73 before the gain partially faded.
Volume behavior supports the speculative-trading read. Turnover has been erratic all month, with sessions ranging from a few thousand shares to more than 370,000, and multi-percentage-point gaps between consecutive prints are routine. Against that backdrop, a 4.48% move is unremarkable for this security.
The fundamental backdrop that produced the preceding selloff is worth restating. The third-quarter report filed November 13 showed no revenue for the nine months to September 30, operating expenses up 39% to $3.1 million, and a net loss of $3.3 million. It also disclosed that disclosure controls were not effective because of a material weakness tied to related-party transaction approvals, and confirmed that a Nasdaq Staff Delisting Determination received July 15 remains unresolved after an August 25 Hearings Panel hearing. Stockholders' equity of $7.8 million now clears the $2.5 million minimum, but cash of $7.7 million against a multi-million-dollar annual burn keeps dilution risk live, with roughly 27.2 million warrants and about 20.2 million as-converted preferred shares sitting ahead of 10.5 million common shares.
The move was company-specific rather than sector-driven, and it does not reflect any verified development among dermatology or consumer-wellness peers. Activity was elevated relative to normal turnover for the name, though the tape remains dominated by small lot sizes and wide spreads.
Technically, the shares are trading well below their 50-day and 200-day moving averages near $1.14 and $1.15, and remain roughly 62% below the 52-week high of $1.84. Today's bounce is consistent with a short-term oversold rebound off the $0.60-$0.61 area rather than a change in trend, and the failure to hold the intraday high near $0.73 shows sellers remain active on strength.
The score runs from 0, meaning no meaningful news and a price move that is normal for the stock, to 100, meaning transformative news paired with an extreme and rare move. Caring Brands scores 6 out of 100.
The news component is weak by any measure: nothing verifiable was published on the day, and the only recent fundamental disclosure — the quarterly report — was negative and had already driven the stock sharply lower over the following sessions. The price component is equally muted. Today's 4.48% gain is roughly eight-tenths of the stock's 5.6% average absolute daily move over the past 60 sessions, and moves of this size or larger occurred in 23 of the past 69 sessions. A routine swing in an already volatile nano-cap therefore combines with an absence of news to produce a very low score.
The most immediate scheduled unknown is the Nasdaq Hearings Panel's decision on the company's continued listing, which was not disclosed in the November 13 filing and could arrive at any time. Additional closings under the $9 million convertible preferred purchase agreement are expected on a rolling basis and would add supply, while a resale registration covering roughly 24.5 million shares represents a further overhang.
Operationally, investors will focus on whether the new salesforce and marketing campaigns produce the first meaningful product revenue after a nine-month period with none, and on the pace of cash consumption against the $7.7 million balance. The next scheduled fundamental update is the full-year 2026 report, which last year was filed at the end of March. No analyst coverage or consensus estimates exist for the name, so headline risk will come from filings and listing developments rather than from guidance. The principal risks remain financing dilution, delisting, and the possibility that today's rebound, like several before it this month, fades within days.
Tickeron's Trending AI Robots page curates the automated strategies performing strongest under current market conditions. The platform offers hundreds of AI trading bots spanning thousands of tickers, but only a select group is featured here at any time, with bots differentiated by strategy type, trading timeframe, performance metrics, and the symbols they trade. For traders navigating volatile small caps, it is a practical starting point for comparing live, rules-based approaches side by side. Explore the curated list to see which bots are leading right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CABR saw its Momentum Indicator move below the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator turned negative. In 24 of the 26 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CABR turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 12 similar instances when the indicator turned negative. In 11 of the 12 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CABR moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CABR entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
CABR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. CABR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.906) is normal, around the industry mean (6.379). P/E Ratio (-1.308) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. CABR's P/S Ratio (10000.000) is very high in comparison to the industry average of (183.387).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsGeneric